Cbd Hemp Vape Oil

Niiranen Aila Mattson K: A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 1985; 8: 336-40. CrossRef MEDLINE e50.

Herman TS Einhorn LH Jones SE et al.: Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. Cbd Hemp Vape Oil n Engl J Med 1979; 300: 1295-7. MEDLINE e44. Johansson R Kilkku P Groenroos M: A double-blind controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Can Treat Rev 1982; 9: 25-33.

Niederle N Schutte J Schmidt CG: Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr 1986; 64: 362-5. CrossRef MEDLINE e49.

The effect of nabilone on neuropsychological functions related to driving ability: an extended case series. Hum Psychopharmacol 2005; 20: 291-3. MEDLINE e118.

CrossRef MEDLINE 21. Kosel BW Aweeka FT Benowitz NL et al.: The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002; 16: 543-50. CrossRef MEDLINE 22. Engels FK de Jong FA Sparreboom A et al.: Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 2007; 12: side effects after stopping cannabis 291-300.

Treatment of Tourette’s syndrome with ?9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002; 35: 57-61 MEDLINE e109. Müller-Vahl KR Schneider U Prevedel H et al.

Duran M Prez E Abanades S et al.: Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 2010; 70: 656-63. MEDLINE e36. Ahmedzai S Carlyle DL Clader IT Moran F: Anti-emetic efficacy and toxicity of nabilone a synthetic cannabinoid in lung cancer chemotherapy. Br J Cancer 1983; 48: 657-63. MEDLINE PubMed Central e37. Chan HS Correia JA MacLeod SM: Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind crossover trial.

Smoked medicinal cannabis for neuropathic pain in HIV: a randomized crossover clinical trial. Neuropsychopharmacology 2009; 34: 672-80 MEDLINE e83. Ware MA Wang T Shapiro S et al.: Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182: 694-701 MEDLINE e84. Karst M Salim K Burstein S Conrad I Hoy L Schneider U: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.

Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Sympt Manag 1995; 10: 89-97. MEDLINE e61. Timpone JG Wright DJ Li N et al.

Engels FK de Jong FA Sparreboom A et al.: Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 2007; 12: 291-300. CrossRef MEDLINE 23.

Rog DJ Nurmikko TJ Friede T Young CA: Randomized controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812-9 CrossRef MEDLINE e78. Nurmikko TJ Serpell MG Hoggart B Toomey PJ Morlion BJ Haines D: Sativex successfully treats neuropathic pain characterised by allodynia: a randomised double-blind placebo-controlled clinical trial.

Duran M Prez E cannabis tincture recipe topical Abanades S et al.: Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 2010; 70: 656-63. MEDLINE e36. Ahmedzai S Carlyle DL Clader IT Moran F: Anti-emetic efficacy and toxicity of nabilone a synthetic cannabinoid in lung cancer chemotherapy. Br J Cancer 1983; 48: 657-63. MEDLINE PubMed Central e37. Chan HS Correia JA MacLeod SM: Nabilone versus prochlorperazine Cbd Hemp Vape Oil for control of cancer chemotherapy-induced emesis in children: a what temp does cannabidiol vape at double-blind crossover trial.

Zajicek J Fox P Sanders H et al.: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-26. MEDLINE e3.